Foghorn Therapeutics (FHTX) Other financing activities (2019 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Other financing activities came in at $89000.0 in Q1 2026, down 35.97% year-on-year from $139000.0 in Q1 2025, and up 117.07% quarter-over-quarter from $41000.0 in Q4 2025.
Foghorn Therapeutics (FHTX) Other financing activities (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Other financing activities history runs 8 years deep, the most recent figure standing at $89000.0 for Q1 2026.
- On a quarterly basis, Other financing activities fell 35.97% year-over-year to $89000.0 in Q1 2026; TTM through Mar 2026 was $433000.0, a 72.66% decrease from a year earlier, with the FY2025 full-year figure at $483000.0, down 81.51% from the prior year.
- Other financing activities grew to $89000.0 in Q1 2026 per FHTX's latest filing, from $41000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $1.4 million in Q3 2024 and bottomed at $4000.0 in Q4 2024.
- The 5-year median for Other financing activities is $162500.0 (2023), against an average of $420312.5.
- Across the five-year window, Other financing activities tumbled 99.96% in 2022 and surged 1062.5% in 2023, its largest moves.
- Year by year, Other financing activities stood at $16000.0 in 2022, then jumped by 1062.5% to $186000.0 in 2023, then plunged by 97.85% to $4000.0 in 2024, then jumped by 925.0% to $41000.0 in 2025, then jumped by 117.07% to $89000.0 in 2026.
- Per Business Quant, the three latest FHTX Other financing activities figures stand at $89000.0 (Q1 2026), $41000.0 (Q4 2025), and $49000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89,000.00 |
| Mar 31, 2026 | 89,000.00 |
| Dec 31, 2025 | 41,000.00 |
| Dec 31, 2025 | 41,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 254,000.00 |
| Jun 30, 2025 | 254,000.00 |
| Mar 31, 2025 | 139,000.00 |
| Mar 31, 2025 | 139,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | 1.44 Mn |
| Sep 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Dec 31, 2023 | 186,000.00 |
| Dec 31, 2023 | 186,000.00 |
| Sep 30, 2023 | 1.39 Mn |
| Sep 30, 2023 | 1.39 Mn |